Biolase (BIOL) reported a wider Q1 loss on declining revenues versus a year ago, and shares rose more than 1%.
The maker of dental lasers blamed a host of factors for its shrinking revenues, including a director dispute, shareholder litigation and IRS depreciation rules on dental equipment.
The company reported an adjusted Q1 net loss of $0.11 per share vs. a net loss loss of $0.07 in the year-ago period, on revenues of $11.5 million vs. $14.6 million.
No analyst estimates were available.
In mid-day trade, BIOL was up 1.56% to $1.95.
Latest posts by Kevin Calderon (see all)
- AMD Epyc Processor Units – A Rival for Intel? - Jun 22, 2017
- Climate Change Study Had To Be Postponed Due To The Severe Ice Conditions - Jun 15, 2017
- Aldi Is Planning On Increasing Its Presence In The US Market - Jun 12, 2017